Adaption of an Episomal Antisense Silencing Approach for Investigation of the Phenotype Switch of Staphylococcus aureus Small-Colony Variants

Nina Schleimer¹, Ursula Kaspar¹, Britta Ballhausen¹, Sarah A. Fotiadis¹, Jessica M. Streu¹, André Kriegeskorte¹, Richard A. Proctor² and Karsten Becker¹*

¹ Institute of Medical Microbiology, University Hospital Münster, Münster, Germany, ² Departments of Medical Microbiology/Immunology and Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI, United States

Staphylococcus aureus small-colony variants (SCVs) are associated with chronic, persistent, and relapsing courses of infection and are characterized by slow growth combined with other phenotypic and molecular traits. Although certain mechanisms have been described, the genetic basis of clinical SCVs remains often unknown. Hence, we adapted an episomal tool for rapid identification and investigation of putative SCV phenotype-associated genes via antisense gene silencing based on previously described Tn10-encoded tet-regulatory elements. Targeting the SCV phenotype-inducing enoyl-acyl-carrier-protein reductase gene (fabI), plasmid pSN1-AS'fabI' was generated leading to antisense silencing, which was proven by pronounced growth retardation in liquid cultures, phenotype switch on solid medium, and 200-fold increase of antisense 'fabI' expression. A crucial role of TetR repression in effective regulation of the system was demonstrated. Based on the use of anhydrotetracycline as effector, an easy-to-handle one-plasmid setup was set that may be applicable to different S. aureus backgrounds and cell culture studies. However, selection of the appropriate antisense fragment of the target gene remains a critical factor for effectiveness of silencing. This inducible gene expression system may help to identify SCV phenotype-inducing genes, which is prerequisite for the development of new antistaphylococcal agents and future alternative strategies to improve treatment of therapy-refractory SCV-related infections by iatrogenically induced phenotypic switch. Moreover, it can be used as controllable phenotype switcher to examine important aspects of SCV biology in cell culture as well as in vivo.

Keywords: Staphylococcus aureus, small-colony variant (SCV), antisense silencing, phenotype switch, enoyl-acyl-carrier-protein reductase gene (fabI), tet-regulatory expression system

INTRODUCTION

The small-colony variant (SCV) phenotype represents a slow growing subpopulation of Staphylococcus aureus associated with chronic, persistent, and recurring infections, which are particularly difficult to diagnose and challenging in terms of treatment (Proctor et al., 2006; Vaudaux et al., 2006; Kahl et al., 2016). The colony morphology and physiological characteristics
of SCVs differ widely from the WT, not only due to slower growth, pinpoint colonies, reduced or no pigmentation and hemolytic activity, respectively, but also in several biochemical traits such as altered expression of virulence factors, decreased respiration and coagulase activity as well as frequently by auxotrophy for hemin, menadione, thymidine, or fatty acids (Proctor et al., 2006; Seggewiß et al., 2006; Kriegeskorte et al., 2011, 2014; Proctor et al., 2014; Schleimer et al., 2018).

The identification of the genetic mechanisms leading to the phenotype switch are prerequisite to prevent SCV-related recurrence and chronic infection and to develop new antimicrobials not selecting for SCVs. Hitherto, however, only some phenotype switch-related genes and mechanisms were identified by in vitro generation of knockout mutants (including accC, accD, aroD, cspB, hemA, hemB, menA, menB, menD, ppxX, sdcAB, and thyA) and sequencing approaches (including accC, accD, aroB, aroC, aroD, ecfA, ecfT, fabF, fabI, hemA, hemB, hemC, hemD, hemE, hemG, hemH, menA, menB, menC, menE, relA, sip, and thyA) (von Eiff et al., 1997; Bates et al., 2003; Schaaff et al., 2003; Chatterjee et al., 2008; Lannergård et al., 2008; Duval et al., 2010; Gao et al., 2010; Gaupp et al., 2010; Parsons et al., 2011, 2013, 2014; Köser et al., 2012; Wakeman et al., 2012; Hammer et al., 2013; Dean et al., 2014; Painter et al., 2015; Lin et al., 2016; Gao et al., 2017; Zhang et al., 2017; Bazaid et al., 2018; Giuliani et al., 2018; Schleimer et al., 2018; Vestergaard et al., 2018). Besides these SCVs triggered by mutational events restricted to one gene locus, SCVs being the consequence of combined mutations in two or more genes were also rarely described (Hammer et al., 2013; Bui and Kidd, 2015; James et al., 2019). Moreover, the differential expression of some key transcriptional regulators such as SigB and non-protein-coding RNAs (npcRNAs) were shown to contribute to the phenotype switch (Moisan et al., 2006; Abu-Qatouseh et al., 2010; Mitchell et al., 2013; Bui and Kidd, 2015; Tuchserr et al., 2015). Nevertheless, the (potential) genetic mechanisms of several clinical SCVs remain unidentified and knockout mutant generation and sequencing approaches including whole genome sequencing (WGS) are time-consuming. Moreover, selective disruption of genes essential for growth is not feasible. Aggravating the analysis of clinical SCVs so far, indubitable identification of genes causative for the phenotype switch is only possible for stable SCVs that already underwent mutational adaption and by comparison with a revertant phenotype that spontaneously emerged from the SCV phenotype (Becker et al., 2006; Schleimer et al., 2018). Besides the rarely isolated stable clinical SCVs, in vitro selection for stable SCVs mandatory for WGS as well as for transcriptomics and proteomics can be performed by cultivation in the presence of sublethal concentrations of certain antibiotics (e.g., aminoglycosides) (Balwit et al., 1994) or by serially passaging bacteria in the presence of HeLa cells using modified gentamicin protection assays (McLean et al., 2019). By using these methods, however, the SCV-selective mutations only occur in the corresponding drug target genes or genes essential for antibiotic uptake (Schaaff et al., 2003; McLean et al., 2019). Further approaches selecting for a stable SCV phenotype include a chemostat to generate steady-state growth conditions with low nutrients and low growth rate for a prolonged time and with specific chemical stress (Bui and Kidd, 2015; Bui et al., 2015). Although this is an adequate method, it is also time-consuming and not applicable in every laboratory. Thus, there is an urgent need for simpler, faster, and more cost-effective methods to identify genes that trigger the phenotype switch upon mutational or transcriptional inactivation or downregulation.

Inducible gene expression systems comprising repressor and operator regulatory elements have been reported for use in the genus *Staphylococcus* for selectively controlling the (over)expression of genes (Wieland et al., 1995; Ji et al., 1999; Jana et al., 2000; Helle et al., 2011). Amongst these, tetracycline- (Tc) or anhydrotetracycline (ATc)-inducible expression plasmids comprising improved elements originating from the transposable element Tn10 were used not only for overexpression, but also for regulated antisense silencing of distinct genes (Ji et al., 1999, 2004; Stary et al., 2010; Helle et al., 2011). This study focused on the adaption of the expression plasmid pRAB11 (Helle et al., 2011) for the identification of genes potentially triggering the phenotype switch from WT to SCV. Therefore, we developed an ATc-inducible antisense approach outlined in Figure 1. This tet-regulatory system is based on autoregulated expression of the repressor TetR, which is responsible for the adequate regulation of a target gene. TetR attaches to the cognate operator sequences within both its own promoter and in the divergently located promoter of the target gene, thus, inhibiting the transcription of the target gene (Meier et al., 1988). Upon binding of the effector, TetR undergoes a conformational change and the detachment from the operator proceeds (see Figure 1).

Using the further improved shuttle plasmid pSN1, silencing of the SCV phenotype-related gene fabI (encodes for enoyl-carrier-protein reductase) via production of antisense RNA was performed in a one-plasmid setup. Application of this type of episomal silencing system may provide an easy-to-use and fast tool for the identification of phenotype switch-related genes. The identified genes producing the SCV phenotype will not only allow the screening of clinical SCV isolates, in particular those with undefined auxotrophy, for mutations in these genes by simple Sanger sequencing. Furthermore, knockout mutant generation of the identified genes may also contribute to the identification of possible new auxotrophies and thus to the characterization of undefined SCV types, further simplifying the identification of SCVs. Another advantage of the pSN1 tool is that its inducer ATc is able to penetrate cell membranes. Thus, it may not only help to develop future alternative treatment options of therapy-refractory SCV-related infections, e.g., by iatrogenically induced phenotypic switch, but will also offer the opportunity to monitor the effects and consequences of the switching process on the host cell, organs, and the host organism. Finally, this tool may enable the fast suitability analysis of potential new drug target genes regarding their influence on an adverse phenotype switch to the SCV.
**MATERIALS AND METHODS**

**Bacterial Strains and Plasmids, Growth Conditions, and Antibiotics**

All strains and plasmids used are listed in Table 1. *Escherichia coli* cells were cultivated and grown at 37°C in liquid or on solid Luria-Bertani medium (LB; Becton Dickinson, Franklin Lakes, NJ, United States). *S. aureus* strains were grown at 37°C in tryptic soy broth/agar (TSB/TSA; Becton Dickinson) or on Columbia blood agar (BBL™ Columbia agar with 5% sheep blood; Becton Dickinson). All liquid cultures were incubated with shaking at 160 rpm in 10 or 50 mL TSB in 100- or 500-mL glass baffled flasks, respectively. Ampicillin (Sigma-Aldrich, St. Louis, MO, United States) was used at a final concentration of 100 µg/mL for selection of *E. coli*. Chloramphenicol (AppliChem, Darmstadt, Germany) was used at a final concentration of 5 µg/mL for selection of *S. aureus*. ATc (IBA Lifesciences, Göttingen, Germany) was purchased in dry chemical form, prepared as 10 mM stock solution in 70% ethanol and used as effector agent at a final concentration of 0.4 µM.

**Genetic Manipulation in *E. coli* and *S. aureus***

One Shot™ Top10 chemically competent *E. coli* cells (Invitrogen/Thermo Fisher Scientific, Waltham, MA, United States) were used for propagation and cloning experiments. Transformation of *E. coli* was performed using standard techniques (Hanahan, 1983) and plasmid DNA cloned in *E. coli* was isolated with the Qiagen Plasmid Mini kit (Qiagen, Venlo, Netherlands) and used to transform restriction-deficient *S. aureus* RN4220 by electroporation (Augustin and Götz, 1990). Subsequently, plasmid DNA was introduced into *S. aureus* SA113 by electroporation. All constructed plasmids were verified after each cloning step via standard-PCR amplification using plasmid-specific oligonucleotides pSN1-F (5′-CTGGGCGAGTTTACGGGTTG-3′) and pSN1-R (5′-CAC ATGCAGCTCCCGGAGAC-3′) covering the *tet*-regulatory elements and, if present, the *fabI* fragment. The reaction conditions for standard-PCRs using Taq DNA polymerase (Segenetic, Borken, Germany) were 4 min initial denaturation at 95°C followed by 31 cycles of (i) denaturation at 95°C for 30 s, (ii) annealing at 58°C for 30 s, and (iii) extension at 72°C for 1 min. Analysis of PCR and restriction products was performed by agarose gel electrophoresis and purification using the QIAquick PCR Purification kit (Qiagen). This was followed by Sanger sequencing (Eurofins Genomics, Ebersberg, Germany). Restriction enzymes used for cloning were obtained from New England Biolabs (Frankfurt am Main, Germany). Genomic DNA of NCTC8325-4 was extracted after lysostaphin treatment (20 µg/mL, 1 h, 37°C) (Wak-Chemie Medical, Steinbach, Germany) using the QIAamp DNA Mini kit (Qiagen).
Secondary sequence structure prediction was performed using the Mfold web server (Zuker, 2003) with default settings. The structure exhibiting the lowest ΔG was used for further analyses.

**Construction of Plasmids for Episomal Silencing of Gene fabI**

To introduce two base substitutions within the −10 site of promoter P_{tetR} in pRAB11, a 90-bp sequence comprising promoter P_{tetR} (Geissendörfer and Hillen, 1990) framed by XbaI and XhoI sites was chemically synthesized and cloned into the multiple cloning site (MCS) of pEX-A2 (Eurofins Genomics) to yield pEX-A2-P_{tetR}. Since restriction via XbaI and XhoI was not practicable, P_{tetR} was amplified with oligonucleotides P_{tetR}-F (5′-GGCGGCCTAGACATCATATTCCT-3′) and P_{tetR}-R (5′-GGCGCTCGAGGGGATCCAAATAA-3′) (restriction sites are written in bold) from pEX-A2-P_{tetR} via standard PCR followed by restriction with XbaI and XhoI. For the construction of pSN1, the XbaI-XhoI synthetic P_{tetR} sequence (see Figure 1C) was cloned into pRAB11 replacing P_{tetR} and generating pSN1 that was transformed into *S. aureus* SA113 to generate SAS99/1.

For the construction of plasmid pSN1-AS′fabI′, a 382-bp fragment of the N-terminal region of the fabI gene (SAOUHSC_00947, corresponding to nucleotides 18 to 399) was amplified from genomic DNA of NCTC8325-4 using oligonucleotides fabI-AS-F-EcoRI (5′-GGCGCGAATTCCAAAAACATATGCATCATTGGGAAT-3′) and fabI-AS-R-KpnI (5′-GGCGCGTACCTTAAAGCTCATGAG GCACAAT-3′) (restriction sites are written in bold) and the EcoRI/KpnI-digested PCR product was ligated in antisense orientation downstream of P_{tetR} via P_{tetR} promoter-operator fusion into the EcoRI and KpnI sites within the MCS of pSN1.

### Table 1: Bacterial strains and plasmids with their precursors used in this study.

| Strain or plasmid | Description | Source or references |
|-------------------|-------------|---------------------|
| **S. aureus strains** | | |
| NCTC8325-4 | NCTC8325 derivative; agr^+; 11-bp deletion in rabU; cured of three prophages | Novick, 1967; Herbert et al., 2010 |
| RN4220 | NCTC8325-4 derivative; agr^-; 11-bp deletion in rabU; cured of three prophages; MNNG: r^-m^- | Iordanescu and Surdeanu, 1976; Herbert et al., 2010 |
| SA113 | NCTC8325 derivative; agr^-; 11-bp deletion in rabU; point mutation in tcaR; three prophages, Phi1, Phi2, and Phi3; MNNG: r^-m^- | Iordanescu and Surdeanu, 1976; Herbert et al., 2010 |
| SAS32/1 | SA113 pRAB11 | This study |
| SAS99/1 | SA113 pSN1 | This study |
| SAS118/2 | SA113 pSN1-AS′fabI′ | This study |
| **pALC2073** | shuttle plasmid; pALC2073 derivative with mutated Staphylococcus shuttle plasmid; pSN1 derivative carrying a 382-bp fragment of *Staphylococcus* shuttle plasmid; pRMC2 derivative with Staphylococcus shuttle plasmid; pRAB11 derivative with Staphylococcus shuttle plasmid; pCPP-3 derivative carrying an 800-bp fragment from *Staphylococcus* shuttle plasmid; pSK236 derivative with 800-bp fragment from *Staphylococcus* shuttle plasmid; pSN1-AS′ | Invitrogen/Thermo Fisher Scientific |
| **pCPP-3** | shuttle plasmid; derived from plasmids pBR322, pUB10 and pC194; neo | Band et al., 1983 |
| **pWH353** | shuttle plasmid; pCPP-3 derivative carrying an 800-bp fragment comprising Trn10 derived elements tetR (encoding the TetR repressor) and P_{tetR} (mutant tetR promoter with poly-A block and improved tetO) with 1x tetO; cloned into the pPrf and Smal sites; bla cat | Geissendörfer and Hillen, 1990 |
| **pSK236** | shuttle plasmid; pUC19 cloned into the HindIII site of pC194; bla cat | (unpublished data) Tinsley and Khan, 2007 |
| **pALC2073** | shuttle plasmid; pSK236 derivative with 800-bp fragment from pWH353 comprising tetR, P_{tetR}, and P_{tetO} with 1x tetO; cloned into the Pefl and Smal sites; bla cat | Bateman et al., 2001 |
| **pRMC2** | shuttle plasmid; pALC2073 derivative with mutated −10 sequence within the tetR promoter (5′-tagaaat-3′ → 5′-tataaat-3′; P_{tetO}) and extended MCS (KpnI, Hpal, BglII, SacI, BamHI, and EcoRI); tetR, P_{tetO} and P_{tetO} with 1x tetO; bla cat | Corrigan and Foster, 2009 |
| **pRAB11** | shuttle plasmid; pRMC2 derivative with tetR, P_{tetO}, and P_{tetO} with 2x tetO; bla cat | Heile et al., 2011 |
| **pEX-A2** | standard plasmid; pUC ori; bla | Eurofins Genomics |
| **pEX-A2-P_{tetR}** | standard plasmid; pEX-A2 derivative with 90-bp synthetic fragment comprising P_{tetR} framed by XbaI and XhoI; bla | This study |
| **pSN1** | shuttle plasmid; pRAB11 derivative with tetR, P_{tetR}, and P_{tetO} with 2x tetO; bla cat | This study |
| **pSN1-AS′fabI′** | shuttle plasmid; pSN1 with 382-bp fragment of fabI cloned in antisense orientation in the EcoRI and KpnI sites downstream of P_{tetO} with 2x tetO; bla cat | This study |

1 Precursor plasmids of pRAB11. 2 Kindly provided by Ralph Bertram, Department of Microbial Genetics, University of Tübingen, Tübingen, Germany.
The verified construct was subsequently transformed into SA113 yielding SAS118/2. Further fabI fragments with 75-bp, 100-bp, 150-bp, 200-bp, and 300-bp in size originating from different regions of fabI with and without the Shine-Dalgarno sequence were additionally amplified (used oligonucleotides and characteristics of each antisense “fabI” fragment are listed in Supplementary Tables S1, S2, respectively), cloned into plasmid pSN1, and transformed into SA113.

RESULTS AND DISCUSSION
Since SCV-caused infections are difficult to treat, it is of major interest to identify and characterize those genes, which are involved in the phenotypic switch from the WT to the SCV phenotype. However, the approaches used so far for this purpose are expensive, time-consuming, and/or difficult in handling. Moreover, clinically derived strain pairs consisting of both stable SCVs and revertant WTs are prerequisites. Therefore, this study focused on the generation of an easy-to-handle genetic tool for the rapid identification of SCV phenotype generation-related genes.

In our study, we adapted the Tn10-encoded Tc- or ATc-inducible tet-regulated repressor-operator expression system, which was first described in E. coli and then modified in several ways to meet the different requirements for Gram-positive bacteria (reviewed in Bertram and Hillen, 2008). For episomal antisense silencing of phenotype-related genes in S. aureus (see Figure 1), we employed plasmid pRAB11 (Helle et al., 2011) containing the tet-regulatory elements tetR (encodes the repressor), its enhanced autoregulated promoter PtetR (Geissendörfer and Hillen, 1990; Corrigan and Foster, 2009), and the divergently located promoter-operator fusion Psyl/tet with two tetO sequences (Geissendörfer and Hillen, 1990; see Figure 1). Since for fatty acid metabolism-related gene fabI, mutations were already shown to be responsible for the phenotype switch to the SCV (Bazaid et al., 2018), we exemplarily used this gene in our experiments. Initial experiments to determine the suitability of pRAB11 unexpectedly revealed pronounced growth retardation for strain SAS32/1 carrying the empty pRAB11 upon induction with the effector ATc (Figure 2). ATc represents a derivative of Tc, but since growth of SA113 in ATc-containing TSB was not affected, its low antibiotic activity...
(Degenkolb et al., 1991) was not responsible for the slow growth phenomenon. During generation of plasmid pRAB11 for the use in Gram-positive bacteria, several modifications were performed (see Table 1; Geissendörfer and Hillen, 1990; Bateman et al., 2001; Corrigan and Foster, 2009; Helle et al., 2011). Amongst these, adaptation of the −10 sequence within the tetR-driving promoter $P_{tet}^\ast$ formally designed by Geissendörfer and Hillen (1990) resulted in the consensus sequence (5′-taggt-3′ → 5′-tataat-3′) (Corrigan and Foster, 2009), but unintentionally led to a disruption of its palindromic tetO sequence (see Figure 1C) and therefore, presumptively resulted in increased amounts of TetR due to loss of its negative regulation (Stary et al., 2010). Whilst increased amounts of TetR provide improved repression for $P_{xyl}$, promoter constructs harboring only one tetO (Corrigan and Foster, 2009) in the uninduced state, these high TetR concentrations may be toxic to the cells (Lutz and Bujard, 1997) as the unbound TetR homodimers are freely available in the induced state. Furthermore, since induction of the $P_{xyl/tet}$ promoter may be negatively affected by overexpression of TetR (Ehrt et al., 2005), we adapted the system by restoring the tetO1 sequence within the TetR promoter generating plasmid pSN1. S. aureus cells harboring pSN1 (SAS99/1) showed no signs of growth retardation in presence of ATc (Figure 3) presumptively linked to the fact that, due to the restored tetO1, the negatively controlled transcription of tetR by TetR as in its original state (Yang et al., 1976; Beck et al., 1982; Wissmann et al., 1988) is reconstituted.

For episomal antisense silencing, a 382-bp fragment of the gene fabI mostly congruent with fragments used before (Li et al., 2004; Stary et al., 2010) was cloned downstream of promoter $P_{xyl/tet}$ in pSN1. Induction with ATc resulted in distinct retardation of growth (Figure 3) as shown before with chromosomally encoded tetR (Stary et al., 2010) as well as for episomal silencing with a plasmid harboring a leaky (Zhang et al., 2000) one-tetO-version that was induced with Tc (Ji et al., 2004). Phenotypic characterization of fabI antisense silencing on solid agar revealed colonies exhibiting the SCV phenotype only upon induction with ATc (Figure 4). The SCV phenotype was more pronounced on agar containing 0.4 µM ATc than on agar with 0.2 µM ATc. However, on agar with 0.4 µM ATc, SCVs were heterogeneous in size with 74.83% micro-SCVs, 19.14% mini-SCVs, and 3.73% SCVs, respectively. This differentiation into different SCV phenotypes despite the same treatment and environmental conditions is a phenomenon known for SCVs and implicates an adaption strategy during the infection and persistence process (Tuchscherr et al., 2011). It was therefore expected that the bacterial cells have the ability to react slightly different to the silencing of a particular gene and the environmental conditions. Unaffected WT cells remained to react slightly different to the silencing of a particular gene and the environmental conditions. Unaffected WT cells remained to react slightly different to the silencing of a particular gene and the environmental conditions. Unaffected WT cells remained to react slightly different to the silencing of a particular gene and the environmental conditions. Unaffected WT cells remained to react slightly different to the silencing of a particular gene and the environmental conditions. Unaffected WT cells remained to react slightly different to the silencing of a particular gene and the environmental conditions.
and 2.30% for 0.4 μM ATc. This may indicate that some of the cells were able to escape induction with ATc, which needs to be further investigated. Since qPCR showed a considerably elevated expression of antisense ‘fabI’ only for strain SAS118/2 in the induced state (~200-fold increase compared to induced control strain SAS99/1, both measured after 2 h of growth) (Figure 5), this indicates functional silencing due to pSN1-derived antisense expression.

Since not all antisense RNA fragments are effective in inhibiting gene expression in S. aureus (Ji et al., 2004), we analyzed several fabI fragments from different regions of fabI with and without Shine-Dalgarno sequence that exhibited 75- to 300-bp in size, a GC content of 29.3 to 36.7% and ΔG values of −45.6 to −11.8 kcal/mol (for comparison, the 382-bp fragment exhibited a GC content of 34.8% and a ΔG of −70.3 kcal/mol; see Supplementary Material). However, a silencing effect could only be observed for the 382-bp fabI fragment, not for any of the other fragments tested (data not shown) as it could be also not shown before for a fragment bigger than 500 bp (Ji et al., 2004). Therefore, contrary to expectations, the presence of the Shine-Dalgarno sequence does not seem to be relevant as it was described for gene silencing in E. coli (Stefan et al., 2008). Secondary sequence structure prediction for each fragment revealed different loop regions with unpaired bases that are complementary and with accessible conformation to hybridize with fabI mRNA (data not shown). Even though some of these fragments showed loop regions of a bigger size compared to the 382-bp fabI fragment, this seemed to have no impact on silencing. Instead, the quantity of loop regions may contribute to silencing, as the 382-bp fabI fragment exhibited 20 loops compared to 4 to 16 loops of the other fragments (see Supplementary Material). Therefore, antisense silencing seems to depend significantly on fragment size and target region. Thus, the final effectiveness of the fragments is difficult to predict necessitating further examinations.

CONCLUSION

Our results demonstrate the crucial role of TetR and its major importance in negative regulation of repressor expression for episomal antisense silencing. However, to perform efficient antisense silencing, size and region of the antisense fragment complementary to the region of the target gene remain critical factors that need further detailed investigations. Plasmid pSN1 allowed antisense silencing of the fabI gene in an easy-to-handle one-plasmid setup. Due to the MCS directly downstream of the inducible P_xyl/tet promoter, genes of interest can easily be cloned into the plasmid. Moreover, the two-tetO P_xyl/tet version exerted a tight repression of the gene of interest in the uninduced state, thus there is no necessity of chromosomal tetR integration prior to use. Also other SCV characteristic (e.g., hemolysis behavior, coagulase and protease production, as well as antibiotic resistance) can be analyzed with this system as already shown for antisense silencing of hla (encodes for α-toxin) (Ji et al., 1999). Owing to induction with ATc, pSN1 mediated antisense silencing may not only be applicable to different S. aureus backgrounds, but also in cell culture studies (Ji et al., 1999; Bateman et al., 2001). Therefore, pSN1 mediated antisense silencing may not only help to identify SCV phenotype-related genes but also to analyse the consequences of the switching process to the host cells and organs.

DATA AVAILABILITY

All relevant data for this study are included in the manuscript and/or the Supplementary Files.

AUTHOR CONTRIBUTIONS

KB and AK designed the study concept. NS, AK, and BB designed the experiments. NS performed the laboratory work, evaluated the data, and drafted and wrote the manuscript. UK contributed to the data evaluation and writing of the manuscript. SF and JS contributed to the laboratory work. RP provided the scientific support regarding SCVs and interpreted the data. All authors have read and approved the final draft of the manuscript.

FUNDING

This research was supported in part by a grant to KB (BE 2546/1-2) from the Deutsche Forschungsgemeinschaft (DFG).

ACKNOWLEDGMENTS

We would like to thank Ralph Bertram from the Department of Microbial Genetics, University of Tübingen, Tübingen, Germany for the generous gift of plasmid pRAB11. Furthermore, we are grateful to Melanie Bach and Daniela Kuhn for excellent technical assistance. This manuscript is part of the Ph.D. thesis entitled “Staphylococcus aureus Small-Colony Variants – Insights in Formation and Antibiotic Susceptibilities” by NS (2019).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2019.02044/full#supplementary-material

REFERENCES

Abu-Qatouseh, L., Chinni, S., Seggewiß, J., Proctor, R. A., Brosius, J., Rozhdestvensky, T. S., et al. (2010). Identification of differentially expressed small non-protein-coding RNAs in Staphylococcus aureus displaying both the normal and the small-colony variant phenotype. J. Mol. Med. 88, 565–575. doi: 10.1007/s00109-010-0597-2
Augustin, J., and Götz, F. (1990). Transformation of *Staphylococcus epidermidis* and other staphylococcal species with plasmid DNA by electroporation. *FEMS Microbiol. Lett.* 66, 203–207. doi: 10.1111/j.1574-6968.1990.tb09979.x

Ballhausen, B., Kriegeskorte, A., Schlieker, N., Peters, G., and Becker, K. (2014). The msrA Homolog msrC Confers Resistance against β-Lactams in *Staphylococcus aureus* irrespective of the genetic strain background. *Antimicrob. Agents Chemother.* 58, 3791–3798. doi: 10.1128/AAC.02731-2713

Balwit, J. M., van Langevelde, P., Vann, J. M., and Proctor, R. A. (1994). Identification of point mutations in clinical *Staphylococcus aureus* small-colony variants in persistent infections. *Antimicrob. Agents Chemother.* 38, 2283–2290. doi: 10.1128/AAC.01786-1789

Ehrt, S., Guo, X. V., Hickey, C. M., Ryou, M., Monteleone, M., Riley, L. W., et al. (2005). Controlling gene expression in mycobacteria with anhydroretrecyclase and Tet repressor. *Nucleic Acids Res.* 33,321. doi: 10.1093/nar/gni013

Gao, W., Chu, K., Davies, J. K., Newton, H. J., Seemann, T., Harrison, P. F., et al. (2010). Two novel point mutations in clinical *Staphylococcus aureus* reduce lincosamide susceptibility and switch on the stringent response to promote persistent infection. *PLoS Pathog.* 6:e1000944. doi: 10.1371/journal.ppat.1000944

Gaupp, R., Schlag, S., Liebeke, M., Lalk, M., and Götz, F. (2010). Advantage of upregulation of succinate dehydrogenase in *Staphylococcus aureus* Biofilm. *J. Bacteriol.* 192, 2385–2394. doi: 10.1128/JB.01472-1479

Geissendorfer, M., and Hillen, W. (1990). Regulated expression of heterologous genes in *Bacillus subtilis* using the Tn10 encoded tet regulatory elements. *Appl. Microbiol. Biotechnol.* 33, 657–663. doi: 10.1007/BF00064933

Giulieri, S. G., Baines, S. L., Guerillot, R., Seemann, T., Gonçalves da Silva, A., Schultz, M., et al. (2018). Genomic exploration of sequential clinical isolates reveals a distinctive molecular signature of persistent *Staphylococcus aureus* bacteraemia. *Genome. Med.* 10:65. doi: 10.1186/s13073-018-0574-x

Hammer, N. D., Reniere, M. L., Cassat, J. E., Zhang, Y., Hirsch, A. O., Indriati Hooi, M., et al. (2013). Two heme-dependent terminal oxidases power *Staphylococcus aureus* organ-specific colonization of the vertebrate host. *mBio* 4:e00241-13. doi: 10.1128/mBio.00241-13

Hanahan, D. (1983). Studies on Transformation of *Escherichia coli* with plasmids. *J. Mol. Biol.* 166, 357–580. doi: 10.1016/0022-2836(83)80284-80288

Helle, L., Kull, M., Mayer, S., Martinola, G., Zeller, M.-E., Goerke, C., et al. (2011). Vectors for improved Tet repressor-dependent gradual gene induction or silencing in *Staphylococcus aureus*. *Microbiology* 157, 3314–3332, doi: 10.1099/mic.0.052548-0

Herbert, S., Ziebandt, A.-K., Ohlsen, K., Schäfer, T., Hecker, M., Albrecht, D., et al. (2010). Repair of global regulators in *Staphylococcus aureus* 8325 and comparative analysis with other clinical isolates. *Infect. Immun.* 78, 2877–2889. doi: 10.1128/IAI.00888-10

Jordanceau, S., and Surdeanu, M. (1976). Two restriction and modification systems in *Staphylococcus aureus* NCTC8325. *J. Gen. Microbiol.* 96, 277–281. doi: 10.1099/0022-2836(83)80284-80288

James, K. L., Mogen, A. B., Brandwein, J. N., Orsini, S. S., Ridder, M. J., Markiewicz, M. A., et al. (2019). Interplay of nitric oxide synthase (NOS) and SrrAB in modulation of *Staphylococcus aureus* metabolism and virulence. *Infect. Immun.* 87:e00570-18. doi: 10.1128/IAI.00570-18

Jana, M., Luong, T.-T., Komatsuzawa, H., Shigeta, M., and Lee, C. Y. (2000). A method for demonstrating geneessentiality in *Staphylococcus aureus*. *Plasmid* 44, 100–104. doi: 10.1016/S0032-7875(00)00011-x

Ji, Y., Marra, A., Rosenberg, M., and Woodnutt, G. (1999). Regulated antisense RNA eliminates alpha-toxin virulence in *Staphylococcus aureus* infection. *J. Bacteriol.* 181, 6585–6590.

Kahl, B. C., Becker, K., and Löffler, B. (2016). Clinical Significance and pathogenesis of *Staphylococcus* small colony variants in persistent infections. *Clin. Microbiol. Rev.* 29, 401–427. doi: 10.1128/CMR.00069-15

Köser, C. U., Holden, M. T. G., Ellington, M. J., Cartwright, E. J. P., Brown, N. M., Oglivey-Stuart, A. L., et al. (2012). Rapid whole-genome sequencing for investigation of a neonatal MRSA outbreak. *N. Engl. J. Med.* 366, 2267–2275. doi: 10.1056/NEJMoa1109910

Kriegeskorte, A., Grubmüller, S., Huber, C., Kahl, B. C., von Eiff, C., Proctor, R. A., et al. (2014). *Staphylococcus aureus* small colony variants show common metabolic features in central metabolism irrespective of the underlying auxotrophism. *Front. Cell. Infect. Microbiol.* 4:414. doi: 10.3389/fcimb.2014.00414

Kriegeskorte, A., König, S., Sander, G., Pirkl, A., Mahabir, E., Proctor, R. A., et al. (2011). Small colony variants of *Staphylococcus aureus* reveal distinct protein profiles. *FEMS Microbiol. Lett.* 31, 147–153. doi: 10.1111/j.1574-6968.2010.01673.x

Kriegeskorte, A., König, S., Sander, G., Pirkl, A., Mahabir, E., Proctor, R. A., et al. (2011). Small colony variants of *Staphylococcus aureus* reveal distinct protein profiles. *FEMS Microbiol. Lett.* 31, 147–153. doi: 10.1111/j.1574-6968.2010.01673.x

Lannergård, J., von Eiff, C., Sander, G., Cordes, T., Seggewifl, J., Peters, G., et al. (2008). Identification of the genetic basis for clinical menadione-auxotrophic small-colony variant isolates of *Staphylococcus aureus*. *Antimicrob. Agents Chemother.* 52, 4017–4022. doi: 10.1128/AAC.00668-668
Lin, Y.-T., Tsai, J.-C., Yamamoto, T., Chen, H.-J., Hung, W.-C., Hseuh, P.-R., et al. (2016). Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin. *J. Antimicrob. Chemother.* 71, 1807–1814. doi: 10.1093/jac/dkw060

Lutz, B., and Bujard, H. (1997). Independent and tight regulation of transcriptional units in *Escherichia coli* via the LacO/R, the TetR/O and AraC/I1-I2 regulatory elements. *Nucleic Acids Res.* 25, 1203–1210. doi: 10.1093/nar/25.6.1203

McLean, K., Holmes, E. A., Penewit, K., Lee, D. K., Hardy, S. R., Ren, M., et al. (2019). Artificial selection for pathogenicity mutations in *Staphylococcus aureus* identifies novel factors relevant to chronic infection. *Infect. Immun.* 87, e00884-18. doi: 10.1128/IAI.00884-18

Meier, I., Wray, L. V., and Hillen, W. (1988). Differential regulation of the *Tn10*-encoded tetracycline resistance genes *tetA* and *tetB* by the tandem tet operators O1 and O2. *EMBO J.* 7, 567–572. doi: 10.1002/j.1460-2075.1988.tb02846.x

Mitchell, G., Fugère, A., Pépin Gaudreau, K., Brouillette, E., Frost, E. H., Cantin, A. M., et al. (2013). SigB is a dominant regulator of virulence in *Staphylococcus aureus* small-colony variants. *PLoS One.* 8:e65018. doi: 10.1371/journal.pone.0065018

Moisan, H., Brouillette, E., Jacob, C. L., Langlois-Bégin, P., Michaud, S., and Malouin, F. (2006). Transcription of virulence factors in *Staphylococcus aureus* small-colony variants isolated from cystic fibrosis patients is influenced by SigB. *J. Bacteriol.* 188, 64–76. doi: 10.1128/JB.188.1.64-76.2006

Novick, R. (1967). Properties of a cryptic high-frequency transducing phage in *Staphylococcus aureus*. *Virology* 33, 155–166. doi: 10.1016/0042-6822(67)90185-9

Painter, K. L., Strange, E., Parkhill, J., Bamford, K. B., Armstrong-James, D., and Edwards, A. M. (2015). *Staphylococcus aureus* adapts to oxidative stress by producing *H_{2}O_{2}*-resistant small-colony variants via the SOS response. *Infect. Immun.* 83, 1830–1844. doi: 10.1128/IAI.03016-1014

Parsons, J. B., Frank, M. W., Jackson, P., Subramanian, C., and Rock, C. O. (2014). Incorporation of extracellular fatty acids by a fatty acid kinase-dependent pathway in *Staphylococcus aureus*. *Mol. Microbiol.* 92, 234–245. doi: 10.1111/mmi.12595

Parsons, J. B., Frank, M. W., Rosch, J. W., and Rock, C. O. (2013). *Staphylococcus aureus* fatty acid auxotrophs do not proliferate in mice. *Antimicrob. Agents Chemother.* 57, 5729–5732. doi: 10.1128/AAC.00383-1013

Parsons, J. B., Frank, M. W., Subramanian, C., Saenkhum, P., and Rock, C. O. (2011). Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. *Proc. Natl. Acad. Sci. U.S.A.* 108, 15378–15383. doi: 10.1073/pnas.1102081108

Proctor, R. A., Kriegeskorte, A., Kahl, B. C., Becker, K., Löffler, B., and Peters, G. (2014). Artificial tetracycline resistance via the LacR/O, the TetR/O and AraC/I1-I2 regulatory elements. *EMBO J.* 33, 155–166. doi: 10.1038/emmm.201000115

Proctor, R. A., von Eiff, C., Heilmann, C., Proctor, R., Woltz, C., Peters, G., and Götz, F. (1997). A site-directed *Staphylococcus aureus hemB* Mutant is a small-colony variant which persists intracellularly. *J. Bacteriol.* 179, 4706–4712. doi: 10.1128/JB.179.15.4706-4712.1997

Wakeman, C. A., Hammer, N. D., Staff, D. L., Attit, A. S., Anzaldi, L. L., Dakol, S. I., et al. (2012). Menaquinone biosynthesis potentiates haem toxicity in *Staphylococcus aureus*. *Mol. Microbiol.* 86, 1376–1392. doi: 10.1111/mmi.12063

Wieland, K.-P., Wieland, B., and Götz, F. (1995). A promoter-screening plasmid and xylene-inducible, glucose-repressible expression vectors for *Staphylococcus carnosus*. Gene 158, 91–96. doi: 10.1016/0378-1119(95)00137-U

Wissmann, A., Meier, I., and Hillen, W. (1988). Saturation mutagenesis of the Tn10-encoded tet operator O1: identification of base-pairs involved in Tet repressor recognition. *J. Mol. Biol.* 202, 397–406. doi: 10.1016/0022-2836(88)90273-2

Yang, H.-L., Zubay, G., and Levy, S. B. (1976). Synthesis of an R plasmid protein associated with tetracycline resistance is negatively regulated. *Proc. Natl. Acad. Sci. U.S.A.* 73, 1509–1512. doi: 10.1073/PNAS.73.5.1509

Zhang, P., Wright, I. J., Osman, A. A., and Nair, S. P. (2017). An arsD Ochre mutation results in a *Staphylococcus aureus* small colony variant that can undergo phenotypic switching via two alternative mechanisms. *Front. Microbiol.* 8:1001. doi: 10.3389/fmicb.2017.01001

Zuker, M. (2003). Mfold web server for nucleic acid folding and hybridization prediction. *Nucleic Acids Res.* 31, 3406–3415. doi: 10.1093/nar/GK595

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Schleimer, Kaspar, Ballhausen, Fotiadis, Streu, Kriegeskorte, Proctor and Becker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.